Helping Biotron to Do Better and Deliver Tangible Results: Shareholders Call for ASIC Action and Regulatory Scrutiny, page-3

It is the responsibility of all stakeholders — shareholders, staff members, and the wider investor community — to communicate openly with both ASIC and Biotron, with the shared goal of seeing the company succeed. We genuinely wish Biotron every success, and we also want to hope the management team, including the CEO, can deliver meaningful, transparent progress.

That said, the recent decision to raise capital through extreme dilution — offering new shares at just $0.003 — has significantly damaged the value of existing shareholders’ investments. Many long-term investors feel frustrated, excluded, and concerned. They did not participate in the raise, not because they don’t believe in the company’s science, but because they’ve lost confidence in the way the company is being managed and how funds are being raised without results.

You, I, and Biotron staff who are also shareholders (excluding the CEO) all have a responsibility to raise these concerns. This is not about personal attacks. It’s about holding leadership accountable and ensuring ASIC provides the oversight needed to guide the CEO and the C14 process out of the current information vacuum and into full transparency.

Vague language and repeated promises in company announcements are no longer acceptable. Shareholders are not against the CEO — on the contrary, we want to see her succeed. But we also want her to move beyond comfort and routine and focus on delivering actual, measurable outcomes that benefit all shareholders, not just insiders.

This is not about blame. It’s about accountability, performance, and restoring trust — not through words, but through actions and results.